Credits Available: 4.75 AMA PRA Category 1 Credit™/ MOC Points

Description: This curriculum examines the latest advancements in antibody-drug conjugate (ADC) therapy for metastatic triple-negative breast cancer (mTNBC) and HER2-low (HR+/HER2-) breast cancer. It provides insights into mechanisms of action, emerging clinical data, and strategies for integrating ADCs into treatment regimens to improve patient outcomes. Expert-led discussions and case-based learning will support clinicians in individualizing therapy and addressing real-world challenges in ADC use.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse Practitioner, Physician Associate/Assistant, Nurse, Pharmacist, Respiratory Therapist
Target Specialties: Oncology, Hematology/Oncology

Valentia Sterlin

NYU langone
NP hematology oncology

I have been in medical field for the past 18 years. Started my Carrier at Maimonides medical center as Register nurse at Oncology inpatient unit. I have been doing my degree and working inpatient oncology. I moved to work as RN research RN around 2016 at Memorial Sloan Kettering. I finished my MSN NP 2016 and promoted as NP leader at Breast cancer research at MSKCC. I then, moved to NYU langone where I am working now for the past 4 years. I am working with all types of tumor type cancer and hematological and non hematological malignancies. I have autonomy to see patients independently and prescribe different treatment plans, managing patient's symptoms, Presenting patient's cases at tumor boards and gaining my knowledge every day by reading medical journals, doing CEUs , listening RTP with Dr. Love, ASCO and other. I do find that doing CEUS is the best approach for clinicians to get knowledge and staying up to date.